Poll Results

What percent of drug manufacturers will increase production of drug products in the US?

0%: 0%

1-10%: 14%

11-20%: 43%

21-30%: 29%

More than 30%: 14%

When do you feel that a COVID-19 vaccine will become available?

Less than 12 months: 8.3%

12 to 18 months: 66.7%

18 to 24 months: 25.0%

More than 24 months: 0%

Never: 0%

What impact will the coronavirus (COVID-19) have on the pharmaceutical supply chain due to API sourced from China?

High impact: 73%

Some impact: 18%

Low impact: 9%

No impact: 0%

With the approval of more biosimilars, how likely is the FDA to create an authorized generic pathway for BLAs?

Highly likely: 28.6%

Somewhat likely: 42.8%

Somewhat unlikely: 14.3%

Highly unlikely: 14.3%

If the proposed drug importation regulations are passed, what percent of the drug costs will be saved through products purchased under this regulation?

0%: 10%

1-10%: 90%

11-25%: 0%

>25%: 0%

How likely are payers to focus on formulary placement or exclusion for unapproved products (i.e. medical foods)?

Somewhat likely for exclusion purposes only: 72%

No change in focus from today: 14%

Unlikely: 14%

Highly likely: 0%

Biosimilars have gotten off to a slow start in the marketplace. What change will most dramatically affect the adoption rate?

PBM Formulary and coverage decisions: 83%

New Legislation: 17%

HHS/CMS Policy Changes: 0%

Who will be the slowest to adopt the electronic real-time benefit check?

Physicians: 53.8%

PBMs: 30.8%

EMRs: 15.4%

Surescripts: 0%

If the NADAC survey of pharmacy costs becomes mandatory, how will this impact the NADAC and Medicaid pharmacy reimbursement?

NADAC would decrease, resulting in lower Medicaid reimbursements to pharmacies:  88%

NADAC would not change and Medicaid reimbursements would remain the same:  12%

NADAC would increase, resulting in higher Medicaid reimbursements to pharmacies:  0%